ArticleMolecular therapy : the journal of the American Society of Gene Therapy2026
Herbacetin as a novel therapeutic agent for pulmonary and renal fibrosis by targeting TGFBR2 for degradation.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Post-translational protein S-palmitoylation in renal tubular injury: mechanisms and therapeutic implications.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rhodiola rosea L. is a traditional Chinese medicine used clinically to treat pulmonary fibrosis. Due to the presence of multicomponents in Rhodiola rosea L., the mechanism of its anti-fibrotic effect remains unclear. Here, we identified that herbacetin from Rhodiola rosea L. is an active molecule with anti-fibrotic effect in two mouse models of bleomycin-induced pulmonary fibrosis and unilateral ureteral obstruction-induced renal fibrosis. We also uncovered the molecular mechanism through which herbacetin exerted its anti-fibrotic effect by inhibiting transforming growth factor beta (TGF-β)/Smad3 signaling. We found that herbacetin could bind to the transforming growth factor beta receptor 2 (TGFBR2) and induced its degradation via the lysosomal pathway following K48-linked ubiquitination, thereby suppressing TGF-β/Smad3 signaling. Thus, herbacetin is a novel anti-fibrotic agent and exerts its anti-fibrotic effect on pulmonary and renal fibrosis by targeting TGFBR2 for degradation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.